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Targets for new personalized therapeutic
treatmentsSporadic thoracic aortic aneurysms (TAA) and dissections are one of themajor causes of morbidity andmortality
worldwide, especially in those older than 65 years. The presentation of TAA is varied and often silent. Thus,
sporadic TAA detection is often fortuitous, with identiﬁcation occurring during a routine physical examination
or during an unrelatedmedical evaluation. Once suspected, conﬁrmation by imaging clinical approaches is need-
ed to allow the choose of the unique treatments for TAA, namely the surgery procedures, including elective sur-
gery or endovascular repair before the onset of catastrophic and fatal complications, such as dissection or rupture.
At present, there are no biomarkers available to identify TAAs before visible symptoms. However, recent pro-
gresses in understanding of molecular and cellular mechanisms involved in the patho-physiology of sporadic
TAA are suggesting different molecular pathways and their genetic variants as potential biomarkers, which
might be applied into TAA clinical practice in the near future. Here, we report literature evidence on somedisease
pathways and their genetic variants on TAA susceptibility and compliances, and their translation as promising
TAA preventive and prognostic biomarkers and targets for new personalized therapeutic treatments.
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.1. Introduction
Aortic aneurysms occur in thoracic and abdominal sections of aorta
and are a deadly late-age-at onset disease with a very complex patho-
physiology. Both thoracic aortic (TAA) and abdominal aortic aneurysms
(AAA), are also characterized to be silent and asymptomatic diseasesand insidious in their progression [1,2]. Despite these common aspects,
the two aorta pathologies show a signiﬁcant heterogeneity in their
prevalence, distribution along aorta length, age-at-onset, male:female
ratio of disease susceptibility and pathophysiology, as reported in detail
in Table 1 [3]. Thus, TAA and AAA are two distinct pathological entities.
Accordingly, diverse recommendations for diagnostic imaging evalua-
tions, and medical and surgical treatments for TAA and AAA have been
suggested by 2014 European Society Cardiology (ESC) Guidelines (see
2 C.R. Balistreri / Vascular Pharmacology 74 (2015) 1–10Table 2) [4]. On the other hand, one of the major points of these guide-
lines is the inclusion of the entire aorta (thoracic and abdominal) study,
that led the ESC, and for theﬁrst time, to insert indications for AAA diag-
nosis and management [4].
These clinical measures and concepts all correlate with the rising ev-
idence that the large heterogeneity of TAA and AAA is due to the differ-
ent embryological origin of cell lineages in two portions of aorta [1,5].
Speciﬁcally, thoracic aorta originates from neuronal crests, while ab-
dominal aorta derives from splanchnic mesoderm, as illustrated in
Fig. 1 [5]. Disease susceptibility also varies in two aorta sections, with
abdominal aorta beingmore prone to atherosclerosis and aneurysm for-
mation than thoracic aorta. Underlying genetic factors contributing to
two diseases also differ based on the site of the clinical manifestation,
as well as their weight (see Fig. 1) [1,5–7]. Accordingly, it has been evi-
denced that genetic determinants may inﬂuence AAA development.
Heritability estimations as high as 70% have been found, and recently,
several genes and loci have been associated with AAA (CNTN3,
CDKN2BAS, CDKN2A, HSPG2, CSPG2, and sortilin-1 [SORT1] locus) (see
Table 3) [8–11]. Furthermore, in 2013 van de Luijtgaarden and co-
workers, and for the ﬁrst time, analyzed the role of nine genes (the
transforming growth factor-beta pathway genes — EFEMP2, FBN1,
SMAD3, TGBF2, TGFBR1, TGFBR2-, and the smooth muscle cells genes-
ACTA2, MYH11 andMYLK) associated with familial TAA in 155 AAA pa-
tients. They found only three genetic variants as pathogenetic or likely
pathogenic among a total of 47 variants in these genes. Precisely, they
observed one pathogenic and segregating variant (the p.Arg491X in
COL3A1 gene), one likely pathogenic and segregating variant (the
p.Arg254Cys inMYH11 gene), and ﬁfteen variant unknown signiﬁcance
(VUS) in two familial AAA patients, and one pathogenic variant
(p.Ile525Phefs*18) in TGFBR2 gene and seven VUS in a patient with spo-
radic AAA (see Table 2) [11]. These data conﬁrm the reduced contribu-
tion of genetic factors in AAA onset and the AAA different pathogenesis
than TAA. Indeed, AAA is a very complex disorder, whose onset is linked
not only to genetic predisposition, but prevalently to lifestyle-associated
risk factors, including hyperlipidemia, hypertension, sex, age. In addition,
smoking is generally regarded as the most important risk factor [10].
In contrast, genetic factors lie at the basis of TAA formation [12,13].
Accordingly, about 20% of TAA cases show classicMendelian inheritance
with high or complete penetrance and a positive familial history. Famil-
ial TAAD can be subdivided into syndromic presentations that show
prominent features of a systemic connective tissue disorder (such
as Marfan, Loeys–Dietz and Ehlers–Danlos syndrome) and non-Table 1
Heterogenous features in two aorta aneurysms (AAA and TAA).
Different features
Abdominal aortic aneurysm
(AAA)
Thoracic aortic aneurysm
(TAA)
Inheritance Controversial 20% of cases shows classic
Mendelian inheritance with
high or complete penetrance
Incidence 3.9% in men
(65–75 years)
0.7% in women
10.4/100.000
Gender Prevalence 1.3%8.9% in men
1.0%–2.2% in women
3%–4% in individuals older
than 65 years
Male/Female ratio 6:1 1.6:1
Age of onset 75 years 65 years
Anatomical onset
aortic tracts
Infrarenal 50% Ascending, 10% arch and
40% descending
Pathophysiology Inﬂammation, smooth muscle
cell apoptosis, reactive oxygen
species, extracellular matrix
degradation, and activation of
matrix metalloproteinases
Perturbed extracellular
matrix signaling cascade
interactions, deﬁcient
intracellular components of
the smooth muscle
contractile apparatus and
deregulation of transforming
growth factor-β cytokine
(TGF-β) pathway are the key
TAAD mechanismssyndromic presentations (such as bicommissural aortic valve with
TAA, and isolated familial TAA). Seven susceptibility loci have been asso-
ciated with TAA syndromic and non-syndromic forms (see Table 3)
[12–16]. Related-genes have revealed that perturbed extracellular ma-
trix signaling cascade interactions, deﬁcient intracellular components
of the smooth muscle contractile apparatus and deregulation of
transforming growth factor-β cytokine (TGF-β) pathway are the key
TAA mechanisms (see Table 3) [2,17–20]. The involvement of TGF-β
pathway has particularly opened unexpected new investigation ways
for familial TAA forms. Pathogenesis of familial TAA forms is, indeed,
today better understood. As result, the management strategies for the
medical and surgical treatment of familial TAAs are becoming increas-
ingly gene-tailored [4,15]. In addition, these pathogenetic insights
have delivered new treatment options (i.e. angiotensin receptor
blockers, which are antagonists of TGF-β signaling pathway, to reduce
aorta dilatation), that are currently investigating in large clinical trials
[21–23]. On the other hand, this is suggested by 2014 ESC guidelines [4].
Of course this discussion on the genetics of aorta aneurysms would
result incomplete without considering sporadic forms of TAA. On the
other hand, sporadic TAAs represent the major number of TAA cases.
Their incidence is also increasing in our population, especially in aged
subjects [17,18,24]. As consequence, sporadic TAA is becoming a com-
mon and serious health risk. Despite this, it still is not clear the weight
of genetic component in its susceptibility. A very limited number of ge-
netic studies have been until now executed. As consequence, it is difﬁ-
cult to make generalizations about the disease pathways or genetic
risk factors contributing to sporadic TAA forms. Molecular and genetics
mechanisms of the non-familial TAA forms, still remain largely un-
known. Sporadic TAA is, indeed, considered a pathology by unclear
mechanisms [17,18,24]. Being silent, its detection is often fortuitous,
with identiﬁcation occurring during a routine physical examination or
during an unrelated medical evaluation. Once suspected, conﬁrmation
by imaging clinical approaches is needed to allow the choose of the
unique treatments for TAA, namely the surgery procedures, including
elective surgery or endovascular repair before the onset of catastrophic
and fatal complications (i.e. dissection or rupture), as recommended by
2014 ESC guidelines (see Table 2) [4,17,18,24]. In accordance with this,
here it describes, as instructive example, a case, a 71 year old man, ar-
rived in the out-patient department for a routine health screening for
employment (see Fig. 2 A and B, and related legend). After a meticulous
physical examination, TTEwas performed and permitted to diagnose an
ascending aortic aneurysm of very consistent size (see Fig. 2 A and B).
At present, there are no biomarkers available to identify sporadic
TAAs before visible symptoms. However, it is in increasing the opinion
to consider the sporadic TAA forms as immune/inﬂammatory diseases
with a strong genetic component [25]. As result, a better characteriza-
tion at the molecular level of sporadic TAA is necessary. Firstly, it
might likely lead (i) to early predict and diagnose these diseases in a
more accurate manner. Second, in a near future it might (ii) permit to
translate the genomic information to the clinic, and (iii) improve our
understanding of the disease processes, help us to develop better pre-
ventive and diagnostic tools, and (iv) lead to the design of new ways
to manage sporadic TAA in the era of personalized medicine. This re-
view summarizes for the ﬁrst time the very limited literature data
about genetic studies on sporadic TAA in order to identify disease path-
ways and their genetic variants able to modulate the susceptibility of
sporadic TAA. In addition, evidences about potential associations of in-
ﬂammatory genetic factors with sporadic TAA are also reported in
order to support the current theory of the key role of chronic inﬂamma-
tion in sporadic TAA. This might permit to identify an inﬂammatory
pathway having the role of hub, whose its active stimulation might de-
termine as consequence the onset of sporadic TAA. A very contribution
in the research on sporadic TAA might derive from this discovery and
open new ways, which might be translated in clinical applications as
preventive, diagnostic and prognostic biomarkers and targets for per-
sonalized therapies.
Table 2
Recommendations in diagnostic evaluations and medical and surgical treatments for TAAD and AAA suggested by 2014 ESC Guidelines [4].
Aneurysms Diagnostic approaches Medical treatment Endovascular and surgical treatments
TAAD The guidelines recommend: transthoracic
echocardiogram (TTE) in the assessment of the
aortic root and proximal ascending aorta due to the
improvements in image quality; the transesophageal
echocardiogram (TEE) in evaluation of the rest of the
thoracic aorta; caution in using 3-dimensional
echocardiography because its incremental value in
clinical practice has yet to be evaluated. When an
aortic aneurysm is diagnosed, it is important to
perform computer tomography (CT) or magnetic
resonance imaging to assess the involvement of the
rest of the aorta
In case of aortic dissection, the guidelines maintain
the standard Stanford and De Bakey classiﬁcations
although, in general, they employ the Stanford
classiﬁcation, based on whether or not the ascending
aorta is involved. What is truly novel is the deﬁnition
of a new time-based classiﬁcation that distinguishes
among acute (b14 days), subacute (up to 3 months),
and chronic (more than 3 months) disease.
One of the important contributions of the guidelines
is the assessment of the a priori probability of
ﬁnding dissection in a given patient. The 3 sources of
information (predisposing conditions, type of pain,
and physical examination) are determining factors
in the initial evaluation of the patient. The role of
D-dimers during the early hours of aortic dissection
is also pointed out, although the main limitation is
that they are not elevated in intramural hematoma
or penetrating aortic ulcer. Computed tomography is
undoubtedly the most widely available and accurate
technique for the diagnosis of dissection and is
especially useful for the study of the extension of the
dissection and branch compromise. Nevertheless,
TTE is included as the ﬁrst-line diagnostic technique
since a positive result helps to hasten the application
of the therapeutic strategy. In unstable patients, the
choice between TEE and CT depends on the
availability of experts in the center. The latter would
be indicated in stable patients
With respect to medical treatment in chronically ill
patients, the guidelines stress general measures,
including smoking cessation, blood pressure control
(b140/90 mm Hg), and avoidance of competitive
sports in patients with aortic dilation.
There are some novelties in terms of drug therapy:
treatment with losartan could reduce both the
progression of aortic dilation and aneurysm
formation in Marfan syndrome.
Endovascular treatment might be used for TAAD.
However there are speciﬁc recommendations for
thoracic aorta that refer to proximal and distal
landing zones, which should be at least 2 cm long
and less than 40 mm in diameter. In those patients
with chronic aortic aneurysm, the guidelines
recommend oversizing of the stent diameter by 10%
to 15% with respect to the landing zones. In aortic
dissection, oversizing to any extent is advised
against. During the procedure, the blood pressure
should be lowered and preventive cerebrospinal
ﬂuid drainage should be performed in patients at
high risk of paraplegia
Concerning surgical treatment of aortic dissection,
the guidelines insist that it is indicated in all patients
with type A acute aortic syndrome and stress that
the aim should not only be to save the patient's life,
but also to prevent late reinterventions. On the other
hand, in the presence of organ malperfusion, a
hybrid procedure (surgery and endovascular
treatment or fenestration) may be the best option.
The guidelines also recommend endovascular
treatment in complicated type B aortic dissection
(class I recommendation) and their advice is that
this option be considered in uncomplicated
dissections (class IIa recommendation).
The indications for surgery in patients with
ascending aortic aneurysm have not changed,
except for the deﬁnition of this condition as a risk
factor in patients with Marfan syndrome or
bicuspid aortic valve having an increase in aortic
diameter N 3 mm/year (in previous guidelines, a
growth of N2 mm/year was considered). Although in
patients with Marfan syndrome the indication for
surgery is established when the diameter is
≥50 mm, or
≥45 mm in the presence of risk factors, in those with
bicuspid aortic valve, surgery is indicated when
the diameter of the ascending aorta is ≥55 mm, or
≥50 mm in the presence of risk factors. The
guidelines point out the importance of indexing
the diameters in patients with a small body surface
area, especially in those with Turner syndrome,
and recommend surgery with indexed diameters
N27.5 mm/m2.
AAA The guidelines recommend ultrasound as technique
of choice for the initial study of the abdominal aorta.
Although linear probes are more accurate, those
used in echocardiography enable a correct
assessment in most cases. The anteroposterior
diameter of the abdominal aorta should be measured
from outer edge to outer edge in a circular
transverse image. Due to the variability in the
measurement, it is recommended that variations of
less than 5 mm be interpreted with caution
One interesting aspect is the screening of AAA by
means of abdominal ultrasound. The prevalence
among men over 65 years of age has been calculated
to be 5.5%. On the basis of recent studies,
examination of the abdominal aorta with
conventional echocardiography is recommended, as
AAA are diagnosed in 3.5% to 4% of men aged over
65 years in less than 1 min.
With respect to medical treatment in chronically ill
patients, the guidelines stress general measures,
including smoking cessation, blood pressure control
(b 140/90 mm Hg), and avoidance of competitive
sports in patients with aortic dilation
Concerning drug therapy, guidelines underline that
the use of statins could reduce the progression of
aneurysms
Endovascular treatment might be also used for AAA.
The indications for elective surgery are a
diameter N 55 mm, a growth rate of N10 mm/year,
or the development of symptoms. In smaller
aneurysms, the conservative approach is a better
option than surgery (open or endovascular).
The indication for surgery in women is an especially
complex decision. The rates of rupture for a given
aortic diameter are 3 to 4 times higher in women than
in men, and the aortic diameter at the time of rupture
is, on average, 5 mm smaller.16 For this reason, the
indication for surgery appears to be justiﬁedwhen the
diameter is N50 mm.
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2.1. MMP-pathways
As well recognized, aorta media is composed by vascular smooth
muscle cells (VSMCs) and extracellular matrix (ECM) proteins,primarily elastin and collagen. Maintaining a balanced composition of
VSMCs andECMproteins appears to be critical for preserving the impor-
tant functional properties of the thoracic aorta, especially itsmechanical
compliance with pulsatile blood ﬂow. Disturbances in the molecular
and cellular balance, resulting in excessive ECM degradation, might
lead to progressive aortic wall deterioration, expansion, and rupture
[17,18,24]. Recent studies indicate that VSMCs in condition of endothe-
lium dysfunction participate in remodeling of aortic wall by localized
Fig. 1. TAAD and AAA are two distinct pathological entities. The large heterogeneity in two aorta diseases is principally due to their different embryological origin. Thoracic aorta derives
from neuronal crests and abdominal aorta from splanchnic mesoderm. Disease susceptibility also varies in two aorta sections, with abdominal aorta being more prone to atherosclerosis
and aneurysm formation than the thoracic aorta. Underlying genetic factors contributing to two diseases also differ based on the site of the clinical manifestation, as well as their weight.
4 C.R. Balistreri / Vascular Pharmacology 74 (2015) 1–10production of matrixmetalloproteinase (MMPs) [17,18,24]. MMPs are a
family of more than 20 zinc-dependent proteolytic enzymes [26,27].
They play vital roles in diseases related to ECM metabolism and aortic
wall remodeling, which might be relevant to the development of aneu-
rysms or dissection. In addition, this has led to hypothesize that genetic
variants affecting expression or activity of MMPs might contribute to
thoracic aortic diseases. Accordingly, research groups demonstrated sig-
niﬁcant associations between polymorphisms in MMP genes andTable 3
Susceptibility loci associated with syndromic and non syndromic TAA and AAA.
Chromosomal location Genes
Non-syndromic
TAA
11q23.3-q24 AAT1
5q13-q14 AAT2
15q24-26 AAT6
9q33-q34 TGFBR1
3p22 TGFBR2
16p13.13-p13.12 MYH11
10q23 ACTA2
3p21.1 MYLK
Syndromic
TAA
2q31 COL3A1
15q21.1 FBN1
3p22 TGFBR2
9q33-q34 TGFBR1
15q SMAD3
Abdominal Aortic
Aneurysm
3p12.3 CNTN3
4q31 –
9p21
CDKN2BAS, CDKN2A,
HSPG2, CSPG2
3p22 TGFBR2
16p13.13-p13.12 MYH11
2q31
1p13.3
COL3A1
sortilin-1 (SORT1)sporadic TAA. In particular, in 2006 Chen and colleagues, by genotyping
for−8202A/G, IVS4 + 3G/T, and 2003A/G [Q668R] polymorphisms in
MMP-9 gene 28 patients with degenerative TAA, 60 with dissection
and 111 control patients, observed increased MMP-9 expression in pa-
tients with thoracic aortic diseases. They also found that frequency of
the −8202G allele was signiﬁcantly higher in patients with TAA and
dissection than in control subjects (0.36, P b 0.001). Patients with TAA
and dissection were nearly 5 times more likely than control subjects
to have the G allele (adjusted odds ratio, 4.87; 95% conﬁdence interval,
2.04–11.64). There were no signiﬁcant associations between the
IVS4 + 3G/T or 2003A/G polymorphisms and TAA and dissection [28].
Subsequently, Lesauskaite and colleagues detected eventual associa-
tion of 5A/6A polymorphism in the promoter region of MMP-3 gene
with TAA, in 76 patients (age ranged from 31 to 81 years; median age,
64 years) with dilatative TAA and a random sample of the population
(n = 604). The prevalence of MMP-3 genotypes was similar in the
group of patients with TAA and random sample of population. The
frequency of 5A allele did not differ signiﬁcantly between both groups
and was 0.506 and 0.514, respectively. Male carriers of 5A/5A genotype
were signiﬁcantly younger compared with those with the 6A/6A
genotype [29].
In 2012, Kato and colleagues performed an association study for 95
polymorphisms in 89 candidate genes and TAA in 103 Japanese patients
with this condition. Evaluation of genotype distributions by the
Chi-square test and subsequent multivariable logistic regression analy-
sis with adjustment for covariates revealed that the−340A→ G poly-
morphism (rs514921) of MMP-1 gene was signiﬁcantly (P = 0.0288)
associated with the outcome of TAA, with the minor G allele being
related to a favorable outcome [30].
In 2014, Wang and colleagues assessed the association of 4 single-
nucleotide polymorphisms (SNPs) in MMP-9 and TIMP-3 genes with
Fig. 2.A andB. A 71-year-old Sicilianman arrived in the out-patient department for a routine health screening for employment. After ameticulous physical examination, TTEwas executed
and showed ascending aorta aneurysm of a very consistent size, see A. In B, TTE showed tricuspid aortic valve, with aminimal aortic regurgitation and calciﬁcation on left aortic cuspid. He
had no complaints before presentation. His medical history was signiﬁcant for hypertension. He had no known allergies. His medications included beta blockers and ACE inhibitors.
5C.R. Balistreri / Vascular Pharmacology 74 (2015) 1–10TAD risk in ChineseHan population. A total of 206 Chinese patientswith
thoracic dissection and 180 controls were included in this study. Four
SNPs (rs3918249, rs2274756, rs9609643 and rs8136803) were geno-
typed using high-throughput MALDI-TOF mass spectrometry. The G al-
lele frequency for theMMP-9 SNP rs2274756was signiﬁcantly higher in
female patients than in female controls (P= 0.0099). Moreover, after
adjusting for traditional cardiovascular risk factors (sex, age, hyperten-
sion, dyslipidemia, diabetes and smoking habit), the rs2274756 poly-
morphism (odds ratio: 0.30; 95% conﬁdence interval: 0.11 to 0.79, P=
0.015) resulted in an independent susceptibility factor for dissection
in females. No associations were found between the other SNPs and
this disease [31].
Similar interesting data have been recently obtained in studies per-
formed of my research group on sporadic TAAD. Precisely, we analyzed
161 cases affected by sporadic TAA, 18 cases with thoracic dissectionand 128 controls for three SNPs inMMP-2 andMMP-9 genes. In partic-
ular, we obtained that rs3918242MMP-9 and rs2285053 MMP-2 SNPs
are an independent factor for sporadic TAA and dissection [32,33]. Con-
sistent with these data, increased plasma levels of MMP-9 and MMP-2
were detected in the cases carriers of these SNPs, which positively cor-
relate with elastic fragmentation and the elevated amounts of MMP-9
observed in their tissue aorta samples (r = 0.497, P = 0.0001; r =
0.267, P = 0.03, r = 0.342, P = 0.006, respectively, by non-
parametrical Spearman correlation test; data not shown)[33].
2.2. TGF-β pathway
TGF-β is stored within the matrix and bound by ligands. Upon re-
lease, the peptide dimerizes, binds to cell surface receptors (TGFβ-R I
or II), and initiates an intracellular signaling pathway that terminates
6 C.R. Balistreri / Vascular Pharmacology 74 (2015) 1–10in the nucleus with direct transcriptional regulation. Classically this
signaling pathway utilizes the Smad protein complex and has been as-
sociated with increased production of collagen, elastin, and the tissue
inhibitors of MMPs (TIMPs) for a net effect of ECM synthesis or stabili-
zation. Conversely, via an alternate pathway, (ERK1/2) TGF-β appears
to play amajor role in proteolysis and ECM destruction. In its role as ho-
meostatic regulator of the thoracic aortic ECM, recent data suggest that
TGF-β contributes to TAA formation through modulation of MMP re-
lease and ampliﬁed proteolytic activity [34]. These observations also
have led several groups to indentify associations between polymor-
phisms in TGF-β pathway and aneurysm. An increased number of stud-
ies demonstrated associations of SNPs in TGF-β pathway and abdominal
aorta aneurysms [35,36]. In 2013, Wang and coworkers performed, for
the ﬁrst time, mutational analysis on FBN1, TGFBR1 and TGFBR2 genes
(the threemost common genes causing familial TAA) in 29 TAA Chinese
patients (7 affected families and 22 sporadic patients), and found 21
mutations. In particular, they provided evidence that lack of exon 47
skipping of FBN-1 leads preferentially to cardiovascular defects and
human ancestries inﬂuence genotype–phenotype correlation in TAA
[16].
Subsequently, my research group analyzed the role of ten polymor-
phisms in genes encoding TGF-β isoforms and receptors in sporadic
TAA. Our study included cases affected by sporadic TAA and two control
groups. The most relevant ﬁnding obtained allows us to propose that
rs900 TGF-β2 SNP is associated with sporadic TAA in women, opening
new perspectives for the analysis of sporadic TAA susceptibility factors
and prevention [37].
3. Focus on the role in sporadic TAAD of genetic variants in pathways
related to endothelium dysfunction
3.1. RAS pathway: focus on D/I ACE genetic variant
Components of the renin-angiotensin system (RAS) are heavily
expressed within vascular tissues, and up-regulation of local angioten-
sin II synthesis is associated with adverse autocrine effects on arterial
structure and function, i.e. tissue RAS activity is a major determinant
of vascular tone. Angiotensin II promotes hypertension and alters
shear stress. Experimental data suggest that activation of the RAS may
lead to an increased inﬂammatory response in the vessel wall and to
an activation of MMPs [38].
The synthesis of angiotensin II is performed by a key zinc
metallopeptidase, the angiotensin-converting enzyme (ACE), that cata-
lyzes the conversion of angiotensin I to angiotensin II. ACE is highly
expressed in the aneurysmal vascular wall, in both human disease and
animal models. ACE inhibitors protected against aortic expansion and
rupture in animalmodels of aortic aneurysm. In addition, ACE inhibitors
were associated with a decreased risk of aneurysm rupture in a clinical
study [38]. Thus, ACE might be critical in aortic aneurysm development
because of the relation between the RAS and blood pressure (see
above), which is a known risk factor for aortic aneurysm. The ACE
gene is located in chromosome17q23.3. In intron 16 of this gene, a poly-
morphism comprising an insertion (I) or a deletion (D) of a 287-bp Alu
repeat sequence has been identiﬁed that results in three genotypes:
homozygous DD, II and heterozygous ID [39].
This I/D polymorphism within the ACE gene has been associated
with many diseases, such as myocardial infarction [40]. The ACE I/D
polymorphism could account for approximately half of the observed
variance in ACE levels [39]. Individuals who are homozygous for the D
allele have the highest levels of ACE, those who are homozygous for
the I allele have the lowest and heterozygous individuals have an inter-
mediate level [39]. Many studies have evaluated the association be-
tween ACE I/D polymorphism and aortic aneurysm risk, but the results
are conﬂicting. Thus, two recent meta-analysis have been performed
by Song and colleagues andHuang and colleagues [41,42]. Song and col-
leagues included ten studies (our study included; [32]) with 3557 casesand 5231 controls. The association between ACE I/D genotype and aorta
aneurysm risk was signiﬁcant (OR = 1.30; 95% CI, 1.07-1.57; P b 0.01;
I2 = 68%). When stratiﬁed by ethnicity, a signiﬁcantly elevated risk
was observed in Caucasians (OR = 1.31; 95% CI, 1.07-1.61; P b 0.01;
I2 = 71%). In the abdominal AA subgroup, a signiﬁcantly increased
risk was observed (OR = 1.29; 95% CI, 1.03–1.62; P= 0.02; I2 = 73%).
However, ACE I/D polymorphism was not associated with thoracic an-
eurysm risk (OR = 1.33; 95% CI, 0.85-2.07; P = 0.21; I2 = 52%). Sub-
group analysis on blood pressure status showed that an increased risk
was found in hypertensive patients (OR = 1.52; 95% CI, 1.02-2.26;
P = 0.04; I2 = 0%) but not in normotensive subjects (OR = 1.46;
95% CI, 0.72-2.96; P= 0.30; I2 = 25%) [41].
In the meta-analysis of Huang and colleagues [42], fourteen case–
control studies, including a total of 3938 cases and 5748 controls were
included. Among these studies, a study performed of my research
group was included [43]. This meta-analysis showed a signiﬁcant asso-
ciation between ACE I/D polymorphism and aortic aneurysm risk
(OR=1.53, 95% CI 1.26-1.87, P b 0.01). In the subgroup analysis by eth-
nicity, a statistically signiﬁcant association was found in Caucasians
(OR =1.46, 95% CI 1.20-1.77, P b 0.01), but not in Asians. In the sub-
group analysis by type of aortic aneurysm, this polymorphism was sig-
niﬁcantly associated with AAA risk (OR =1.38, 95% CI 1.10-1.74, P b
0.01), TAA risk (OR=1.59, 95%CI 1.11-2.29, P=0.01) and aortic dissec-
tion risk (OR=2.43, 95% CI 1.07-5.52, P=0.03). Stratiﬁcation by hyper-
tension status showed that hypertensive patientswith this polymorphism
were associated with increased aortic aneurysm risk (OR = 1.47, 95% CI
1.03-2.09, P= 0.03), whereas normotensive individuals with this poly-
morphism did not have an increased aortic aneurysm risk [42].
3.2. NO pathway
Nitric oxide (NO) has multiple effects on vessel wall biology that
could be important in aneurysm pathogenesis, including vasodilatation
and inhibiting smooth muscle migration/proliferation [17,18,24]. The
Nitric Oxide Synthase 3 (NOS3) + 894G N T (Glu298Asp) polymorphism
has been associated with reduced NO production [44]. In addition, var-
iable number of tandem repeat (VNTR) polymorphism in intron 4
(eNOS 4a/b polymorphism), have been shown to affect NOmetabolism
and increase the risk for cardiovascular events [44]. Additionally, this
eNOS gene polymorphism has been also shown to be associated with
hypertension [44].
In 2014, Ekmekçi and colleagues assessed the association of eNOS
gene polymorphisms with aortic dissection. In this study, patients
who underwent surgery with the diagnosis of aorta dissection and sur-
vived after the operation between May 2007 and June 2011 were re-
cruited retrospectively. Among the polymorphisms, the distribution of
eNOS4 a/b gene polymorphism differed signiﬁcantly from the control
group, with higher frequencies of eNOS 4a/a and 4a/b genotypes in
the case group (x(2) = 7.16, P= 0.03) [45].
Signiﬁcant associations were observed in recent studies performed
of my research group between the rs2070744 (−786C/T) eNOs poly-
morphism and sporadic TAA and dissection, by analyzing 18 cases
with dissection, 161 caseswith sporadic TAA and 128 controls. In partic-
ular, higher frequency of−786 T allele was assessed in two case groups
than controls (P = 0.03 and P = 0.00007, respectively by χ2 test). On
the other hand, this SNP located in the promoter region determines a
reduced gene transcription [32,33].
4. Focus on the role in sporadic TAAD of genetic variants in pathways
related to inﬂammation
Recent evidence proposes sporadic TAAD as an immune disease
with a strong genetic component [25]. An active participation of both
innate/inﬂammatory and clonotypic responses has been evidenced.
Inﬁltration of inﬂammatory/immune cells has been actually
identiﬁed through immune-histochemical assays both in the media
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47]. Accordingly, we observed signiﬁcant increased amounts of
CD3 + CD4 + CD8 + CD68 + CD20+ cells in tissue aorta samples
from patients with Stanford type A aortic dissection [32]. Increased
plasma levels of inﬂammatory markers, such as C-reactive protein
(CRP) and inﬂammatory cytokines have been observed in aortic dissec-
tion and sporadic TAA patients [48]. In accordance with these data, we
assessed higher plasma levels of Interleukin-(IL-) 6, Tumor necrosis
factor-α (TNF-α), Interferon (INF)-γ, CRP, MMP-2 and-9 plasma levels
in Stanford type A aortic dissection and sporadic TAA patients than con-
trols (12.66± 2.1 vs. 3.1± 0.99, P b 0.001; 16.78± 1.2 vs. 7.1 ± 2.2, P b
0.0001; 12.13 ± 1.7 vs. 2.1 ± 0.5 P b 0.0001; 14.66 ± 3.2 vs. 4.6 ± 1.67,
P b 0.0001; 56.8 ± 3.8 vs. 12.54 ± 1.6, P b 0.0001; and 59.7 ± 3.7 vs.
11.7 ± 2.6, P b 0.0001, respectively) [32].
Emerging involvement of chronic inﬂammation is leading to identify
inﬂammatory pathways and their genetic variants,whichmight operate
as key link between the onset of sporadic TAA and immune system.
However, no literature data are actually reported about associations be-
tween SNPs in immune/inﬂammatory genes and sporadic TAA. Despite
this, researchers are focussing their attention on an innate immune
pathway, the Toll-like receptor-4 (TLR-4), which has been associated
with the pathophysiology of a large number of CVDs, including athero-
sclerosis, cardiac dysfunction, congestive heart failure and other vascu-
lar diseases, as amply stressed by Frantz and colleagues [49]. Rising
evidence on TLR-4 signaling pathways and TAAD is described below.
4.1. TLR-4 pathway
The TLR-4 pathway is able to recognize both pathogens and endog-
enous ligands. Its structure consists of three domains: an extracellular
leucine-rich repeat (LRR) domain, a transmembrane domain, and an in-
tracellular Toll-interleukin-1 receptor (TIR) domain. The extracellular
LRR domain is involved in recognition of the lipopolysaccharide (LPS)
of Gram-negative bacteria, the prototypic TLR-4 ligand. Other exoge-
nous TLR-4 ligands are the fusion protein of respiratory respiratory syn-
cytial virus and the envelope protein of mouse mammary tumor virus
[50]. In addition, endogenous molecules can directly or indirectly inter-
act with TLR4 pathway, such as heat-shock proteins (HSPs), hyaluronic
acid, β-defensin-2, oxidized-LDL (ox-LDL), ﬁbronectin, and amyloid
peptide [50]. Its activation implies a downstream signaling mediated
by several intracellular adaptor molecules, inducing the activation of
transcription factors, such as Nuclear factor (NF)-kB, and consequently
the production of different inﬂammatory mediators [50,51]. Anti-
inﬂammatory mediators, such as interleukin (IL)-10, are also produced
by the parallel activation of anti-inﬂammatory pathways, which limits
potential tissue damage from excessive activation of the innate immune
system. TLR-4 pathway also triggers instructive immunity. In antigen-
presenting cells, TLR-4 pathway activation induces the expression of
costimulatory molecules and the Major histo-compatibility complex
class II antigens, molecules which contribute to sustain the activation
of instructive responses. Its expression has been also observed on epi-
thelial cells at potential sites of pathogen entry, including skin, respira-
tory, intestinal and genitourinary tract, and on endothelial cells and
smooth muscle cells [50].
As abovementioned, it has been suggested that TLR-4 pathway has a
key role in the pathophysiology of several CVDs [50,52–55]. Recently,
the group of Pasterkamp has provided an overview of the endogenous
molecules, released under cellular cardiovascular stress and damage,
the DAMPs, which can trigger innate immunity via TLR-4-mediated sig-
naling pathway and induce CVD onset as consequence [52]. In addition,
polymorphisms of TLR-4 gene (MIM: 603030), and particularly the
rs4986790 TLR-4 polymorphism, have been associated with the risk of
several CVDs and other age-related diseases, even if contrasting results
have been reported in literature [33,50,52–55].
Recently, it is also emerging its crucial role in age-related aorta dys-
function, aneurysm formation and related complications (dissection orrupture). In particular, recent experimental investigations in animal
and ex vivo models report the role of TLR-4 pathway in the vascular
aorta alterations (vascular remodeling -VR and medial degeneration-
MD) and their complications, such as sporadic TAA. Precisely, they evi-
dence as this pathway evocates or modulates increased expression and
activation of endothelium dysfunction and extra matrix remodeling
aorta pathways [56–64]. Pryshchep and colleagues demonstrated the
TLR4-mediated signaling pathway expression in all cells of arterial
wall and particularly in ECs and VSMCs. In addition, they also evidenced
its functional importance in both mediating physiological aorta homeo-
stasis and maintaining protection, as well as in inducting pathological
aorta phenotypes, such as VR and MD [57,63,64]. Furthermore, Song
and colleagues reported that signaling via TLR-4 pathway and its signal
adaptors (i.e. MyD88) is responsible for the age-elevated basal IL-6 re-
sponse using VSMCs from aged TLR-4-/- and Myd88-/-mice [59]. Eissler
and colleagues observed an increased hypertension related to increased
expression of TLR-4-mediated signaling pathway in vascular cells and
consequent activation of ACE pathway in untreated hypertensive rats
[56]. The group of Golzales-Ramos underlined that circulating Heat
Shock protein 70, associated with an increased cellular aorta's damage,
regulates the proﬁbrotic response of human aorta VSMCs through in-
creased transforming growth factor type-1 (TGF-1) expression,
evocated by TLR-4 signaling pathway [61]. In addition, Li and colleagues
reported the role of TLR-4 signaling pathway in regulating the MMP-9
expression in human VSMCs [58]. Bucci and colleagues recently empha-
sized as the vascular thoracic aorta homeostasis and its alteration in rats
is based on the activity of TLR-4 signaling pathway and its cross talk
with other stress and stretch pathways, including ACE, eNOs, and
MMP pathways [60]. Furthermore, a recent study demonstrated in
apolipoprotein E-deﬁcientmice that it is possible to limit the inﬂamma-
tory process by blocking TLR-4/c-Jun. N terminal kinase signaling path-
way with Rosiglitazone in the initiation stages of aortic aneurysm
development [62].
In complex, these literature data suggest that the TLR-4 pathway
should seem to have a crucial role in sporadic TAA patho-physiology
and represent a crucial link between pathways linked to sporadic TAA
development and immune system, as suggested in our reports [33,50,
52–55]. However, this encouraging and increasing evidence is fruit
prevalently of animal investigations. In addition, no genetic investiga-
tions support its evidence. The gene association study performed by
my group in 2014, indeed, represents the ﬁrst report which, through a
human ex vivo approach, evidenced as some polymorphisms related
to TLR4-mediated signaling pathway signiﬁcantly modulate sporadic
TAA risk [33]. In particular, we found that the rs4986790
(+896A N G) TLR-4 polymorphism confers a higher susceptibility for
sporadic TAA (OR = 14.4, P= 0.0008). Cases bearing the +896A TLR-4
allele showed higher systemic inﬂammatory mediator levels than
other cases and control carriers. This effect increased in cases, which
also were carriers of DACE/-1562TMMP-9/-735TMMP-2 alleles. Thus,
we evaluated eventual differences in the levels of systemic inﬂammato-
ry mediators between cases carriers of +896ATLR-4/DACE/-
1562TMMP-9/-735TMMP-2 alleles (a combined genotype) and cases
no carriers, and between cases and controls. Higher levels of systemic
inﬂammatory mediators in patients with +896ATLR-4/DACE/-
1562TMMP-9/-735TMMP-2 alleles were observed. In addition, they
also had higher plasma levels of MMP-9 and -2 which correlated with
the amounts of MMP-9 and elastic fragmentation observed in their tis-
sue aorta samples. A higher chronic inﬂammatory inﬁltrate was also
found in cases bearing these alleles, which positively correlated with
histological abnormalities and levels of mediators [33]. In addition,
they showed in their tissue aorta samples a typical morphological phe-
notype, characterized by elevated cysticmedial degeneration, plurifocal
medial apoptosis, and increased MMP-9 amounts, and deﬁned in a pre-
vious study as phenotype III [65]. Furthermore, we detected that these
alleles inﬂuence vascular biological aging, evaluating the gold standard
aging marker, the telomere length, in a small number of cases and
Fig. 3. Activation of TLR-4-mediated signaling pathway expressed both on EC and VSMC
cells might determine activation or deregulation of ACE, NO, MMP, TGF-β pathways
(associated with endothelium dysfunction, extracellular matrix remodeling and chronic
inﬂammation) and as consequence sporadic TAA onset. (see Figure 4 of Ruvolo et al.,
2014 study; http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4120489/).
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characterized the 85% of the cases examined,which had lower telomere
length, higher levels of mediators, increased amount of chronic inﬂam-
matory inﬁltrate [33,66,67].
Thus, our results emphasize as a combined risk genotype
(+896ATLR-4/DACE/-1562TMMP-9/-735TMMP-2) associated with
TLR4-mediated signaling pathway is able to modulate the grade of
aorta age-related phenotypical, histological, and systemic abnormalities
and consequently vascular aorta aging, onset, and progression of spo-
radic TAA. They also led us to suggest that this signaling pathway
might also be an optimal target for new therapeutic treatments able
to retard or block the typical aorta age-related changes which deter-
mine endothelial dysfunction, MD, and VR. This might open new per-
spectives for the prevention of both aortic VR and MD and sporadic
TAA, by using combined risk genotype (+896ATLR-4/DACE/−
1562TMMP-9/−735TMMP-2) as optimal genetic biomarker for the ear-
lier detection of this silent pathology in preliminary phases and to treat
with different and speciﬁc therapies depending on individual's geno-
types [33].
However, future andulteriormore large studies are certainly need to
validate the weight of our ﬁndings and suggestions, even if our data are
the result of a relatively small sample and a very homogenous popula-
tion. In addition, gene expression analyses, immunohistochemical
TLR-4 quantiﬁcation, and soluble TLR-4 level detection represent
further objectives of our future studies.
5. Conclusions and perspectives
As summarized in this report, genetic component appears to play a
role in onset and progression of sporadic TAA. Signiﬁcant associations
between some genetic variants in genes of ACE, NO, MMP, TGF-β path-
ways (associated with endothelium dysfunction, extracellular matrix
remodeling and chronic inﬂammation) and sporadic TAA risk have
been described (see Fig. 3). However, number of gene association stud-
ies reported in literature is very limited and consequently inadequate to
evaluate the weight of these genetic factors in susceptibility of sporadic
TAA. Particularly reduced to one or two studies are the investigations on
the role of immune/inﬂammatory SNPs in sporadic TAA. Nevertheless, it
is in increasing the opinion of scientiﬁc community to consider this pa-
thology an immune disease, as well as its evidence [25]. Based on this,
we evaluated, for the ﬁrst time, the role of TLR-4-mediated signaling
pathway and ten related genetic variants in the risk of sporadic TAA
and dissection [32,33]. Interestingly, we found that their combined ge-
notype was signiﬁcantly represented in cases with sporadic TAA than
controls. As result, they led us to suggest the crucial role of this pathway
in the onset of this disease [33]. Likely, activation of TLR-4-mediated sig-
naling pathway expressed both on EC and VSMC cells might determine
activation or deregulation of ACE, NO,MMP, TGF-βpathways (associated
with endothelium dysfunction, extracellular matrix remodeling and
chronic inﬂammation) and as consequence sporadic TAA (Fig. 3). Ac-
cordingly, we postulated a sporadic TAA onset model, that we deﬁned
in Ruvolo et al. study as model of the signaling pathway from the
double-face, given its features (see Fig. 4 of Ruvolo et al., 2014 study
[33]; http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4120489/). We
foretell that it can lead several researchers to perform additional inves-
tigations focused to clear the complex puzzle of this pathology. Reveal-
ing the role of TLR-4-mediated signaling pathway in sporadic TAA may
serve as a starting point for future studies leading to a better under-
standing of the pathophysiological basis and perhaps effective treat-
ment of this human disease. Future studies and additional efforts are,
indeed, imperative as well as a combination of analysis based on genet-
ic, transcriptomic, proteomic and epigenomic evaluations. Epigenomic,
transcriptomic and proteomic approaches could particularly provide
valuable insights about disease pathobiology, although it is very difﬁcult
obtaining human tissue aorta samples and appropriate controls. Thus,
the development of animal models might be a solution to studyhuman aorta diseases by providing the means for testing new pharma-
cological interventions. There is a considerable debate in the ﬁeld of an-
eurysm research about the disadvantages and advantages of the various
rat and mouse models in which aneurysms can be generated in an ex-
perimental setting. These models have provided useful information,
but a model that replicates the chronic disease seen in humans remains
to be produced. Given the unresolved questions, unclear answers and
numerous gaps about the genetic factors, mechanisms and the clinical
management and outcome of sporadic TAA, the solution might be in
looking with new eyes in order to make new discoveries, although,
the way of research to execute is still long and difﬁcult. On the other
hand, Marcel Proust afﬁrmed “The real voyage of discovery consists not
in seeking new landscapes, but in having new eyes.”
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